Is TeleHealth now just 'boring infrastructure?' Valuation Realities and M&A Trajectories
- Nelson Advisors
- 40 minutes ago
- 11 min read
From Headline Story to System Infrastructure: The Commoditisation of Telehealth
Telehealth has completed its transition from a speculative, venture-backed growth category to permanent healthcare infrastructure. Following the unprecedented surge during the early stages of the COVID-19 pandemic, when virtual care claims spiked to 78 times pre-pandemic levels, utilization has settled into a durable equilibrium approximately 38 times higher than pre-2020 baselines. Outpatient and office visit virtualisation has stabilised between 13% and 17% across clinical specialties, representing more than two-thirds of the total care volume originally modelled as virtualisable by industry benchmarks.
This stabilisation marks a fundamental shift in the economics and strategic perception of digital care delivery. Telehealth is no longer evaluated as an independent, disruptive product class capable of commanding venture-style software valuation multiples based on top-line visit volume alone. Instead, live-video consultation and remote triage have become standard features embedded within broader enterprise health systems, commercial payer benefit packages, and electronic health record (EHR) ecosystems.
When basic virtual connectivity becomes ubiquitous, competitive differentiation shifts up the value chain, moving away from the transactional transport layer of connecting a patient to an available clinician via video toward systemic workflow orchestration, continuous data integration, and quantifiable clinical outcomes. Consequently, the industry projection that up to $250 billion in annual U.S. healthcare spend could be digitised is no longer tied to episodic video visits, but to the seamless virtualisation of chronic condition management, home care services, and hybrid care pathways.
This transition to "boring" telehealth is fundamentally beneficial for the broader healthcare ecosystem. It stabilizes care delivery costs, eliminates access friction for geographically isolated populations, such as rural communities where virtual care adoption expanded by 16 percentage points and embeds continuous patient touchpoints into traditional clinical models. However, for standalone digital health "pure-plays" that built business models around transactional, fee-for-service virtual urgent care, this commoditisation represents a structural crisis that mandates immediate operational pivots.
Employer Point Solution Fatigue and the Enterprise Procurement Reset
Corporate health plan sponsors and commercial health plans are driving a rigorous enterprise procurement reset. Driven by compound inflation in commercial medical benefits, where per employee benefit expenses are escalating between 9% and 9.5% annually, pushing total annual costs beyond $18,500 per covered employee—enterprise buyers are actively dismantling the fragmented point solution architectures assembled over the past decade.
The average large enterprise currently manages between 4 and 12 independent digital health vendor contracts spanning virtual primary care, musculoskeletal therapy, diabetes management and digital behavioural health. This point-solution sprawl has created severe administrative complexity, fragmented member health data into disconnected silos, and generated profound engagement friction. Covered employees are frequently forced to navigate up to six distinct health applications, resulting in cognitive fatigue, depressed adoption rates, and unmanaged chronic disease escalation.
Enterprise survey data reveals that 74% of large employers experience high point-solution fatigue, while 84% of employee benefits consultants report active client burnout regarding single condition digital vendors. Crucially, 61% of enterprise buyers explicitly state that standalone point solutions fail to demonstrate verifiable financial return on investment (ROI) or claims-based medical cost reductions. Engagement metrics such as app registrations or active monthly users are no longer accepted by corporate procurement and Chief Financial Officers as valid proxies for economic or clinical value.
Metric / Dimension | Legacy Point Solution Ecosystem | Integrated Enterprise Pathway Platform | Strategic Market Impact |
Vendor Management Volume | 4 to 12+ independent vendor contracts per employer | 1 unified enterprise platform partner | 68% of enterprise CIOs target a minimum 20% vendor reduction. |
Medical Benefit Cost Trend | Exceeds $18,500 per employee (~9.5% annual growth) | Verified claims-based net return (e.g., target 4:1 net ROI) | Elevates health benefits management to a top-tier CFO risk factor. |
Procurement Behaviour | Unbundled purchasing of point features | 51% actively issuing vendor consolidation RFPs | Mandates enterprise vendor re-bundling and outcome-tied pricing models. |
Valuation Revenue Multiple | Compressed multiples (4x–6x revenue) | Premium multiples (6x–8x revenue) | Accelerates distressed M&A and down-rounds for isolated point tools. |
Data Architecture | Siloed, non-interoperable vendor databases | Unified analytics feed integrated into core EHR/Payer systems | Enables bi-directional clinical data exchange and population health management. |
As a direct consequence of this operational strain, 51% of large employers are actively issuing Requests for Proposals (RFPs) to consolidate their vendor landscapes, with 68% of Chief Information Officers targeting a minimum 20% reduction in digital health vendor contracts. Corporate buyers are shifting capital toward enterprise orchestrators, unified digital networks capable of delivering multi-specialty care pathways, integrated data analytics, and risk-bearing or outcome-tied pricing frameworks.
The Embedded Moat: EHR Integrations and Platform Native Virtual Care
A primary engine driving the commoditisation of standalone telehealth platforms is the rapid virtualisation of native Electronic Health Record systems. During the initial virtual care expansion, health systems and medical groups relied on third-party video platforms due to the lack of immediate native infrastructure.
However, enterprise health IT providers, led by Epic Systems, which controls 42.3% of the acute care market and maintains clinical data for over 305 million patient lives—have systematically integrated virtual visit capabilities directly into their core software modules, including MyChart, Haiku, and Hyperspace.
Native EHR integration eliminates the operational friction associated with third-party software portals. Clinicians no longer need to log into disparate external applications, manually transfer encounter notes across non-interoperable systems, or reconcile fragmented billing codes. When a virtual consultation occurs natively within the EHR, schedule coordination, clinical documentation, order entry, e-prescribing, and revenue cycle management occur synchronously within the existing clinical workflow.
Furthermore, enterprise health system platforms are combining native virtual visits with Ambient Clinical Intelligence (ACI) and Large Language Model (LLM) agents. The ACI market, projected to expand from $1.82 billion in 2025 to $18.08 billion by 2035—automates real-time clinical documentation, prior authorisation filings, and medical coding directly during the virtual encounter. Leading enterprise platforms absorb single-feature documentation tools, expanding operational EBITDA margins for provider organisations from historical baseline averages of 15% to 30%.
Against this enterprise software moat, pure-play telehealth providers attempting to sell basic video capabilities back to health systems face severe friction and persistent margin compression. Enterprise software vendors such as Amwell have responded by migrating their client bases away from standalone video products toward modular architectures like Amwell Converge, positioning virtual visits as merely one interface within a broader platform suite of hybrid care delivery and digital clinical workflow software.
Strategic Divergence Among Pure-Plays: Corporate Case Studies
The classification of virtual care as infrastructure has forced a strategic split among pure-play digital health companies. Standalone virtual care providers can no longer rely on generic growth at all costs models, forcing a divergence into two primary survival models: B2B enterprise platform consolidation or vertically integrated consumer specialty care.
Teladoc Health: The Heavy Weight of B2B Transition and D2C Margin Erosion
Teladoc Health demonstrates the complex financial realignments required when transitioning from an early virtual care pioneer to an enterprise B2B platform. Following its $18.5 Billion acquisition of Livongo, Teladoc sought to combine episodic virtual urgent care with continuous, data-driven chronic condition management. However, post-pandemic market dynamics and escalating customer acquisition costs (CAC) exposed deep vulnerabilities in its direct-to-consumer (D2C) mental health brand, BetterHelp.
BetterHelp suffered from severe cost inflation across digital ad channels and increasing consumer price sensitivity, driving accelerated churn in cash pay memberships. This underperformance resulted in massive goodwill impairment write downs, including a $790 Million impairment charge in 2025, which depressed net earnings and highlighted the exposure of unintegrated D2C care models. In response, Teladoc accelerated a strategic pivot for BetterHelp, transitioning the service away from out-of-pocket subscriptions toward in-network commercial insurance coverage. By securing over $150 Million in contracted in-network lives and credentialing more than 8,000 providers, BetterHelp built an annualised insurance revenue run-rate exceeding $110 Million to stabilise its member base.
Concurrently, Teladoc's core B2B segment, Integrated Care, demonstrated stable, enterprise-grade cash generation. Driven by Per Member Per Month (PMPM) enterprise contracts, Integrated Care delivered $394 Million in quarterly revenue with adjusted EBITDA rising 13.6% to $65 Million, alongside a 14% year-over-year expansion in chronic care enrolment reaching 1.27 Million members. Teladoc consolidated these assets under its "Teladoc One" architecture, an AI-enabled model integrating primary care, chronic care, nutrition, and behavioural health. Despite top-line full-year revenue stabilising in the $2.47 Billion to $2.59 billion range, Teladoc's trajectory illustrates the realities of the infrastructure shift: lower top-line growth offset by institutional margin stability and B2B defensibility.
Hims & Hers Health: Vertical Integration and the High-Yield Specialty Cash Model
In contrast to B2B enterprise pivots, Hims & Hers Health achieved hyper growth by bypassing the traditional insurance reimbursement system altogether, establishing a vertically integrated D2C cash-pay model. By focusing on consumer-driven specialty areas, including sexual health, dermatology, hair loss, behavioural health, and weight management, Hims & Hers expanded its revenue trajectory from $1.48 Billion in 2024 toward a projected $2.35 Billion to $2.90 Billion scale by 2026.
The cornerstone of the Hims & Hers model is structural vertical integration that captures software-like gross margins between 75% and 83%. By acquiring Medisource and establishing internal 503B compounding pharmacy facilities, Hims & Hers unified drug manufacturing, clinical telehealth consultation, automated prescription fulfillment, and branded customer experience within a single operational entity. This internal infrastructure reduced supply chain fulfilment times to 1.2 days, lowered cost of goods sold (COGS) by ~12% and enabled custom product formulations, such as personalised multi-condition chewable mints combining cardiovascular and erectile dysfunction actives.
The platform's growth accelerated with its expansion into compounded GLP-1 weight-loss medications (semaglutide and tirzepatide) during brand-name supply shortages. By offering compounded GLP-1 subscriptions at $165–$299 per month, compared to $950to $1,350 for branded pharmaceutical alternatives, Hims & Hers scaled its weight-management subscriber base past 300,000, generating $230 Million in therapy-specific net revenue in 2025. To solidify its international footprint, Hims & Hers entered into a $1 billion agreement to acquire Eucalyptus, capturing an additional $450 Million ARR run-rate across Europe and the Asia-Pacific region.
However, this high-yield cash model carries heightened regulatory and counterparty risks. As brand-name GLP-1 shortages resolve, the FDA enforces strict limits on compounded peptide production, resulting in legal challenges from pharmaceutical manufacturers like Novo Nordisk and forcing immediate pivots toward branded drug options or alternative oral therapies. Hims & Hers demonstrates that while D2C pure-plays can achieve rapid scale, their financial performance remains tightly tied to regulatory compliance, supply chain execution and marketing efficiency.
Telemental Health and Specialty Navigation: Lyra and Included Health
Beyond general primary care, dedicated specialty platforms such as Lyra Health, Spring Health, and Included Health (formed through the merger of Doctor On Demand and Grand Rounds) have carved out defensible enterprise positions by redefining virtual care around clinical triage and navigation.
Recognising that employer spending on digital behavioural health reached $8.2 Billion in 2025 and is projected to surpass $14 Billion by 2030, Lyra and Spring Health deployed precision clinical matching algorithms that compressed time-to-care by 37% relative to traditional Employee Assistance Programs (EAPs). Similarly, Included Health integrated 24/7 virtual urgent care with complex benefit navigation and member advocacy, utilising a hybrid monetisation model where Per Member Per Month (PMPM) enterprise fees comprise ~75% of total revenue.
By embedding virtual consultations within a broader navigation framework that diverts costly emergency department visits (saving an estimated $500–$1,500 per redirected encounter), these specialty platforms defend their pricing power against basic video commoditisation.
Operational Metric / Strategic Axis | Teladoc Health (Integrated Care / BetterHelp) | Hims & Hers Health | Amwell (Converge Platform) | Included Health / Specialty Platforms |
Primary Go-To-Market Model | B2B Enterprise (Payers/Employers) + D2C Insurance Pivot | Direct-to-Consumer Cash-Pay Subscriptions | B2B Enterprise Health System & Payer Software | B2B Enterprise Navigation & Hybrid Specialty Care |
Revenue Scale & Outlook | $2.47B–$2.59B forecast range (Managed growth) | $1.80B–$2.35B+ trajectory (Hypergrowth via GLP-1/Acquisitions) | Enterprise SaaS license & implementation fee mix | High PMPM subscription weight (~75% of total mix) |
Gross Margin Profile | Moderate to High (Compressed by D2C ad costs) | Software-like 75%–83% (Driven by internal compounding) | High software license gross margins | High margin blended enterprise PMPM structure |
Core Operational Infrastructure | Teladoc One platform; virtual multidisciplinary care teams | In-house 503B compounding (Medisource); Proprietary Mobile App | Native EHR-integrated virtual care software suite | Integrated Virtual Urgent Care + Specialty Behavioral Navigation |
Primary Regulatory & Strategic Risk | D2C customer acquisition costs; BetterHelp cash-pay churn | FDA peptide/compounding rules; Big Pharma litigation | Health system IT budget cycles & native EHR feature displacement | Enterprise employer procurement consolidation & ROI proof demands |
What "Boring" Means for the Market: Valuation Realities and M&A Trajectories
The classification of telehealth as standard infrastructure has established a disciplined valuation environment across public and private capital markets. The growth-at-all-costs paradigm that characterised early digital health venture funding has been replaced by strict institutional metrics centred on cash-flow predictability, verifiable clinical ROI and high net revenue retention.
Following a massive VC liquidity deficit of $32.6 Billion in late 2024, the venture capital exit window shifted dramatically. Mergers and Acquisitions (M&A) accounted for 94.7% of all global digital health exits in the first half of 2025, rendering public market initial public offerings (IPOs) accessible only to a select tier of profitable market leaders.
Private equity (PE) firms, holding over $2.5 Trillion in global unallocated dry powder (including more than $1 trillion in the U.S.), have initiated major buy-and-build strategies. Private equity consolidators are systematically acquiring fragmented point solutions and regional health IT assets, integrating ambient AI workflows, and consolidating administrative tools to convert low-margin service assets into high-margin SaaS revenue platforms.
This structural realignment has created a clear division in valuation multiples:
Multi-Product Enterprise Platforms: Companies that demonstrate multi-specialty capabilities, native EHR/payer integration, and outcome-tied pricing models command premium acquisition multiples of 6x to 8x revenue. These platforms are classified by institutional buyers as essential infrastructure components.
Single-Feature Point Solutions: Undifferentiated vendors relying purely on basic video delivery or single-condition tracking experience severe valuation compression, trading at 4x to 6x revenue or lower, frequently facing down-rounds, distressed M&A, or asset liquidation.
Simultaneously, venture funding patterns show a clear flight to scale and technology depth. While total digital health funding recovered to $15.3 Billion, the average deal size expanded more than threefold from $13.6 Million in early 2022 to $46.6 Million in 2026. Capital deployment is heavily concentrated in AI enabled provider operations, revenue cycle management (RCM), and platform scale health tech assets, with AI-driven health tech companies capturing 55% of all venture dollars invested.
Strategic Imperatives for Healthcare Leaders
The transition of telehealth from a headline narrative to core system infrastructure requires immediate adjustments across institutional strategy, operational delivery, and capital allocation. Enterprise healthcare purchasers, provider organisations and digital health operators must align their models with the realities of commoditised virtual care.
For corporate employers and health plan sponsors, the primary directive is the aggressive elimination of point-solution sprawl. Benefits leaders should execute structured vendor consolidation, moving away from fragmented, single-condition applications toward unified enterprise platforms that integrate primary care, mental health, and chronic care management within a single navigation layer. Furthermore, procurement contracts must require verified medical claims data to substantiate vendor ROI claims, transitioning vendor reimbursement toward risk-bearing or outcome-tied structures.
For health system executives and physician organizations, competitive defensibility depends on embedding virtual care directly into native EHR architectures. Provider groups must eliminate independent video tools in favor of integrated clinical software suites that combine native scheduling, e-prescribing, and Ambient Clinical Intelligence. By automating clinical documentation and coding natively during virtual visits, health systems can expand operating margins while building continuous, hybrid care pathways that tie virtual triage directly to physical sites of care.
For digital health founders, pure-play operators, and institutional investors, long-term survival requires moving beyond simple connectivity. Standalone software vendors must either evolve into multi-product enterprise platforms, integrate deeply into core EHR and payer workflows, or establish vertically integrated, high-margin specialty delivery models.
Companies operating direct-to-consumer cash models must maintain rigorous regulatory and compliance frameworks to protect against policy shifts. Ultimately, value creation in digital health no longer stems from virtualising visits, but from orchestrating comprehensive, data-driven clinical care at scale.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments